THIORIDAZINE (MELLARIL) ON REGRESSED SCHIZOPHRENIC PATIENTS
Abstract
The improvement of patients under thioridazine therapy is considered significant in view of the severity and chronicity of their illness and their failure to respond to all previous therapies. An important advantage of thioridazine over chlorpromazine and trifluoperazine is the low incidence of side effects. Because of the results obtained, we feel that further trial of thioridazine (Mellaril) on regressed patients is warranted.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
